Lord’s Mark Industries Biomescan License: Receives Manufacturing Licence for SaMD Platform

What Happened ?

Lord’s Mark Industries Limited informed BSE Limited that it has become the first and only company in India, according to the company’s disclosure, to receive a manufacturing licence for an In Vitro Diagnostic Software (Software as a Medical Device – SaMD) for its Biomescan Analytics Platform. 

The licence has been granted under the Medical Devices Rules, 2017 and marks a regulatory milestone for the company’s efforts to bring gut microbiome science into preventive healthcare and wellness applications. 

key details

Biomescan Analytics Platform:

• Biomescan combines whole metagenome sequencing data with a validated bioinformatics pipeline.
• The platform generates detailed gut microbiome profiles.
• It provides microbiome diversity scores.
• It includes enterotype classification.
• The platform performs functional metabolic assessments.
• It generates evidence-based personalised dietary recommendations. 

Licence & Classification:

The Biomescan platform has been licensed as a wellness and health-information tool under the Software as a Medical Device (SaMD) classification.

The company states that the platform is intended for preventive healthcare and early health risk assessment under the Medical Devices Rules, 2017. 

Strategic Expansion:

Lord’s Mark Industries plans to establish a nationwide network of Health & Wellness Centres in collaboration with:

• Hospitals
• Doctors
• Healthcare institutions

The proposed network is intended to provide personalised microbiome assessments and preventive care strategies using the Biomescan platform. 

Management Commentary:

Managing Director Sachidanand Upadhyay said the company’s vision is focused on shifting healthcare from reactive treatment towards proactive prevention.

Management highlighted the combination of genomics and nutrition as the basis for personalised wellness and said the company intends to work with hospitals and medical professionals across India to make preventive healthcare more accessible. 

Business Implication:

The manufacturing licence provides an important regulatory foundation for Lord’s Mark Industries’ Biomescan initiative. The planned Health & Wellness Centre network could provide the company’s intended route for bringing microbiome-based assessments and preventive healthcare solutions to a wider market.

However, the source document does not disclose revenue projections, commercialisation timelines, expected investment, pricing or financial contribution from Biomescan. 

Note:

• The company describes itself as the first and only company in India to receive this manufacturing licence for an In Vitro Diagnostic Software/SaMD platform.
• This is a statement made in the company’s regulatory disclosure and has not been independently verified here. 

Risk Analysis

Summary:

• The licence is a positive regulatory milestone, but the disclosure does not provide financial estimates or commercialisation details. The eventual business impact will depend on the company’s ability to deploy the platform and establish its proposed healthcare network.

Key Risks:

• The disclosure does not provide expected revenue or profitability from Biomescan.
• The planned nationwide Health & Wellness Centre network is a future strategic objective.
• Commercial adoption of microbiome-based preventive healthcare solutions remains dependent on partnerships and market acceptance.
• The source does not disclose the investment required to establish the proposed network.
• No commercialisation timeline or financial guidance has been provided.

Worst Case:

• If commercial adoption or the planned healthcare-centre expansion progresses slower than expected, the regulatory milestone may take longer to translate into meaningful revenue or earnings contribution.

Risk Level: Medium

Company Commentary

• Managing Director Sachidanand Upadhyay said healthcare is moving from reactive treatment towards proactive prevention.
• Management aims to use scientific health insights to support preventive healthcare before disease develops.
• The company views Biomescan as an integration of genomics and nutrition for personalised wellness.
• Lord’s Mark Industries intends to partner with hospitals and medical professionals across India.
• The company plans to establish a nationwide network of Health & Wellness Centres to make Biomescan-based preventive healthcare solutions more accessible.